Skip to main content
SpringerLink
Log in

Prostanoid Generation in Platelet Function

Assessment and Clinical Relevance

  • Chapter
Platelet Function

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1275 Accesses

Abstract

In response to a variety of proaggregatory stimuli such as thrombin, adenosine diphosphate (ADP), or collagen, platelets synthesize eicosanoids, biologically active metabolites derived from arachidonic acid (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491–1495.

    PubMed  CAS  Google Scholar 

  2. Ueno N, Murakami M, Tanioka T, et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 2001;276:34918–34927.

    Article  PubMed  CAS  Google Scholar 

  3. Matijevic-Aleksic N, Sanduja SK, Wang LH, Wu KK. Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim Biophys Acta 1995;1269:167–175.

    Article  PubMed  Google Scholar 

  4. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.

    Article  PubMed  CAS  Google Scholar 

  5. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634–7639.

    Article  PubMed  CAS  Google Scholar 

  6. Pabla R, Weyrich AS, Dixon DA, et al. Integrin-dependent control of translation: engagement of integrin alphaIIb beta3 regulates synthesis of proteins in activated human platelets. J Cell Biol 1999;144:175–184.

    Article  PubMed  CAS  Google Scholar 

  7. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154:485–490.

    Article  PubMed  CAS  Google Scholar 

  8. Patrignani P, Sciulli MG, Manarini S, et al. Patrignani COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999;50:661–667.

    PubMed  CAS  Google Scholar 

  9. Raychowdhury MK, Yukawa M, Collins LJ, et al. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994;269:19256–19261.

    PubMed  CAS  Google Scholar 

  10. Furci L, Fitzgerald DJ, FitzGerald GA. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. J Pharmacol Exp Ther 1991;258:74–81.

    PubMed  CAS  Google Scholar 

  11. MacIntyre DE, Gordon JL. Calcium-dependent stimulation of platelet aggregation by PGE2. Nature 1975;258:337–339.

    Article  PubMed  CAS  Google Scholar 

  12. Gray SJ, Heptinstall S. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP. Eur J Pharmacol 1991;194:63–70.

    Article  PubMed  CAS  Google Scholar 

  13. Vezza R, Roberti R, Nenci GG, Gresele P. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993;82:2704–2713.

    PubMed  CAS  Google Scholar 

  14. Fabre JE, Nguyen M, Athirakul K, et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001;107:603–610.

    PubMed  CAS  Google Scholar 

  15. Matthews JS, Jones RL. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 1993;108:363–369.

    PubMed  CAS  Google Scholar 

  16. Paul BZ, Ashby B, Sheth SB. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 1998;102:1204–1211.

    Article  PubMed  CAS  Google Scholar 

  17. Ma H, Hara A, Xiao CY, et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001;104:1176–1180.

    Article  PubMed  CAS  Google Scholar 

  18. Murata T Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388:678–682.

    Article  PubMed  CAS  Google Scholar 

  19. Johnson E, Brass LF, Funk CD. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci USA 1998;95:3100–3105.

    Article  PubMed  CAS  Google Scholar 

  20. Funk CD, Furci L, FitzGerald GA. Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci USA 1990;87:5638–5642.

    Article  PubMed  CAS  Google Scholar 

  21. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998;79:691–705.

    PubMed  CAS  Google Scholar 

  22. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309–2315.

    PubMed  CAS  Google Scholar 

  23. Audoly LP, Rocca B, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000;101:2833–2840.

    PubMed  CAS  Google Scholar 

  24. Pratico D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996;271:14916–14924.

    Article  PubMed  CAS  Google Scholar 

  25. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and-2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996;271:12042–12048.

    Article  PubMed  CAS  Google Scholar 

  26. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999;82:794–800.

    PubMed  CAS  Google Scholar 

  27. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–442.

    Article  PubMed  CAS  Google Scholar 

  28. Rocca B, FitzGerald GA. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol 2002;2:603–630.

    Article  PubMed  CAS  Google Scholar 

  29. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54:316–322.

    Article  PubMed  CAS  Google Scholar 

  30. Mahoney TS Weyrich AS, Dixon DA, McIntyre T, Prescott SM, Zimmerman GA. Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes. Proc Natl Acad Sci USA 2001;98:10284–10289.

    Article  PubMed  CAS  Google Scholar 

  31. Zimmerman GA. Two by two: the pairings of P-selectin and P-selectin glycoprotein ligand 1. Proc Natl Acad Sci USA 2001;98:10023–10024.

    Article  PubMed  CAS  Google Scholar 

  32. Thun MJ, Henly SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacological and clinical issues. J Natl Cancer Inst 2002;94:252–262.

    PubMed  CAS  Google Scholar 

  33. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–899.

    Article  PubMed  CAS  Google Scholar 

  34. Andrew DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76–82.

    Article  Google Scholar 

  35. Rocca B, FitzGerald GA. Simply read: erythrocytes modulate platelet function. Should we rethink the way we give aspirin? Circulation 1997;95:11–13.

    PubMed  CAS  Google Scholar 

  36. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997;95:63–68.

    PubMed  CAS  Google Scholar 

  37. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317–327.

    Article  PubMed  CAS  Google Scholar 

  38. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287–1294.

    Article  PubMed  CAS  Google Scholar 

  39. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate thromboxane secretion into the circulation of normal man. J Clin Invest 1986;77:590–594.

    PubMed  CAS  Google Scholar 

  40. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989;992:66–70.

    PubMed  CAS  Google Scholar 

  41. Patrono C, Patrignani P, Rocca B, Landolfi R. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost 1995;74:396–400.

    PubMed  CAS  Google Scholar 

  42. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):234S–264S.

    Article  PubMed  CAS  Google Scholar 

  43. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997;96:1109–1116.

    PubMed  CAS  Google Scholar 

  44. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–1372.

    PubMed  CAS  Google Scholar 

  45. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177–1184.

    PubMed  CAS  Google Scholar 

  46. Baigent C, Patrono C. Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a re-appraisal. Arthritis Rheum 2003;48:12–20.

    Article  PubMed  CAS  Google Scholar 

  47. Bombardier C, Laine L, Reicin A, et al.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–1528.

    Article  PubMed  CAS  Google Scholar 

  48. FitzGerald GA. Coxibs and cardiovascular disease. New Engl J Med. 2004;351:1709–1711.

    Article  PubMed  CAS  Google Scholar 

  49. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987;76:6–14.

    PubMed  CAS  Google Scholar 

  50. Davì G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992;85:1792–1798.

    PubMed  Google Scholar 

  51. Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769–1774.

    Article  PubMed  Google Scholar 

  52. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400–1406.

    Article  PubMed  Google Scholar 

  53. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008–2014.

    Article  PubMed  CAS  Google Scholar 

  54. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera. Evidence for aspirin-suppressable platelet activation in vivo. Blood 1992;80:1965–1971.

    PubMed  CAS  Google Scholar 

  55. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995;74:1225–1230.

    PubMed  CAS  Google Scholar 

  56. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983–989.

    Article  PubMed  CAS  Google Scholar 

  57. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990;63:163–168.

    PubMed  CAS  Google Scholar 

  58. Koudstaal PJ, Ciabattoni G, van Gijn J, et al. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 1993;24:219–223.

    PubMed  CAS  Google Scholar 

  59. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000;102:1007–1013.

    PubMed  CAS  Google Scholar 

  60. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809–1817.

    Article  PubMed  CAS  Google Scholar 

  61. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573–574.

    Article  PubMed  CAS  Google Scholar 

  62. Eikelboom Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650–1655.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center on Physiopathology of Haemostasis, Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy

    Bianca Rocca MD

  2. Department of Pharmacology, University of Rome La Sapienza, Rome, Italy

    Carlo Patrono MD

Authors
  1. Bianca Rocca MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Patrono MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, St. Vincent’s University Hospital, Dublin, Ireland

    Martin Quinn MB BCh BAO, PhD

  2. University College Dublin, Dublin, Ireland

    Desmond Fitzgerald MD, FRCPI, FESC, AAP (Vice President of Research) (Vice President of Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Rocca, B., Patrono, C. (2005). Prostanoid Generation in Platelet Function. In: Quinn, M., Fitzgerald, D. (eds) Platelet Function. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59259-917-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-917-2_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-244-5

  • Online ISBN: 978-1-59259-917-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation